Efficacy of dispersed fibrous carbon sorbent in treatment of malignant fungating wounds

Authors

  • L.A. Sakhno R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • L.P. Babenko Danylo Zabolotny Institute of Microbiology and Virology
  • L.M. Lazarenko Danylo Zabolotny Institute of Microbiology and Virology
  • V.G. Korotych R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • V.V. Sarnatskaya R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • E.A. Snezhkova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • M.Ya. Spivak Danylo Zabolotny Institute of Microbiology and Virology
  • V.G. Nikolaev R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.16757

Keywords:

adsorptive dressing means, carbon dressings, chronic wounds, malignant fungating wounds, wound microbiota, wound odor

Abstract

Summary. Aim: To evaluate the influence of dispersed fibrous carbon sorbent (DFCS) on malignant fungating wounds (MFWs) in Guerin’s carcinoma-bearing rats with an assessment of wound bacterial microflora. Materials and Methods: The study was performed on female Wistar rats inoculated subcutaneously with Guerin T8 carcinoma into the upper interscapular region. On day 20, the tumors were infected by injecting the suspension of S. aureus 8325-4. After 24 h, gauze dressings were applied daily to the wounds in the control group and DFCS in the experimental one. The state of the wounds was assessed by visual control with photo monitoring, odor control on a verbal rating scale and microbiological analysis of qualitative and quantitative characteristics of wound microbiota. Results: On the 3rd day after the start of dressings, the number of S. aureus of 8325-4 strain was significantly higher in the wounds of rats in control group than experimental one (5.14 ± 0.27 vs 3.43 ± 0.33 lg CFU/ml). The total number of Staphylococci in the DFCS-treated wounds did not differ statistically from the number of S. aureus 8325-4 strain whereas in control ones were higher by an order of magnitude. On the 10th day the total number of Staphylococci and S. aureus 8325-4 in particular, remained consistently high in the wounds of the control rats, while was almost five orders of magnitude lower and represented mainly by S. aureus 8325-4 in the experimental ones. The total number of aerobic and optionally anaerobic microorganisms was significantly lower as well. A greater variety of microorganisms in the gauze-covered wounds, as well as an their increased number were accompanied by enhancement of the wound odor from “noticeable” to “strong”. There was an appearance of a “barely noticeable” odor in only one animal from the experimental group. Conclusion: The study has demonstrated the ability of DFCS to control substantially the bacterial microflora as well as malodor of MWFs in vivo. The results obtained can contribute to solving the problem of improving the quality of palliative care for patients with malignant and other chronic wounds.

References

Fromantin I, Watson S, Baffie A, et al. A prospective, descriptive cohort study of malignant wound characteristics and wound care strategies in patients with breast cancer. Ostomy Wound Manage 2014; 60: 38–48. PMID: 24905356

Seaman S. Management of malignant fungating wounds in advanced cancer. Semin Oncol Nurs 2006; 22: 185–93. https://doi.org/10.1016/j.soncn.2006.04.006

Tsichlakidou A, Govina O, Vasilopoulos G, et al. Intervention for symptom management in patients with malignant fungating wounds — a systematic review J BUON 2019; 24: 1301–8. PMID: 31424694

Tandler S, Stephen-Haynes J. Fungating wounds: management and treatment options. Br J Nurs 2017; 22: S6–14. https://doi.org/10.12968/bjon.2017.26.12.S6

Lo SF, Hu WY. The physical, psychological, social, and spiritual impacts of malignant fungating wounds on cancer patient. Hu Li Za Zhi 2008; 55: 75–80 (in Chinese).

Bolton L. Evidence corner: evidence-based care for malignant wounds. Wounds 2016; 28: 214–6. PMID: 27377612

Tilley C, Lipson J, Ramos M. Palliative wound care for malignant fungating wounds: holistic considerations at end-of-life. Nurs Clin North Am 2016; 51: 513–31. https://doi.org/10.1016/j.cnur.2016.05.006

Wilson V. Assessment and management of fungating wounds: a review. Br J Community Nurs 2005; 10: S28–34. https://doi.org/10.12968/bjcn.2005.10.Sup1.17627

Adderley UJ, Holt IG. Topical agents and dressings for fungating wounds. Cochrane Database Syst Rev 2014; 5: CD003948. https://doi.org/10.1002/14651858.CD003948.pub3

Alexander S. Malignant fungating wounds: key symptoms and psychosocial. J Wound Care 2009; 18: 325–9. https://doi.org/10.12968/jowc.2009.18.8.43631

Winardi A, Irwan AMA Systematic review of topical treatment for controlling malignant wound odor. J Eur Wound Manag Assoc 2019; 20: 7–16. https://doi.org/10.35279/jewma201910.01

Gethin G, Grocott P, Probst S, Clarke E. Current practice in the management of wound odour: an international survey. Int J Nurs Stud 2014; 51: 865–74. https://doi.org/10.1016/j.ijnurstu.2013.10.013

Vardhan M, Flaminio Z, Sapru S, et al. The microbiome, malignant fungating wounds, and palliative care. Front Cell Infect Microbiol 2019; 9: 373. https://doi.org/10.3389/fcimb.2019.00373

Fromantin I, Seyer D, Watson S, et al. Bacterial floras and biofilms of malignant wounds associated with breast cancers. J Clin Microbiol 2013; 51: 3368–73. https://doi.org/10.1128/JCM.01277-13

Thuleau A, Dugay J, Dacremont C, et al. Volatile organic compounds of malignant breast cancer wounds: identification and odors. Wounds 2018; 30: 337–44. PMID: 30380523

Darwin ES, Thaler ER, Lev-Tov HA. Wound odor: current methods of treatment and need for objective measures. G Ital Dermatol Venereol. 2019; 154: 127–36. https://doi.org/10.23736/S0392-0488.18.05960-6

Eretskaya EV, Sakhno LA, Nikolaev VG. Application sorption: experience in clinical use and prospects of development. Biomater Artif Cells Immobilization Biotechnol 1991; 19: 129–45. https://doi.org/10.3109/10731199109117821

Sakhno LA, Nikolaev VG, Lozinskaya IA, et al. Basic studies of local adsorption in burn treatment. Biomater Artif Cells Immobilization Biotechnol 1991; 19: 111–28. https://doi.org/10.3109/10731199109117820

Nikolaev VG. Sakhno LA, Snezhkova EA, et al. Carbon adsorbents in oncology: achievements and perspectives. Exp Oncol 2011; 33: 2–8. PMID: 21423088

Nikolaev VG, Samsonov VA. Analysis of medical use of carbon adsorbents in China and additional possibilities in this field achieved in Ukraine. Artif Cells Nanomed Biotechnol 2014; 42: 1–5. https://doi.org/10.3109/21691401.2013.856017

Nikolaev VG. Sorption therapy with the use of activated carbons: effects on regeneration of organs and tissues. In: Chang TMS, ed. Hemoperfusion, Plasma Perfusion and Other Clinical Uses of General, Bispecific, Immune and Leukocyte Adsorbents. World Scientific, 2017: 221–43.

Shevchuk OO, Snezhkova EA, Bilous AG, et al. Detoxification as an addition to conventional therapy of acute radiation sickness and iatrogenic leukopenia. In: Ota Fuchs ed. Cells of the Immune System, Leucocyte Biology. London. Intechopen, 2019: 1–20.

Sakhno L, Pyatchanina T, Shapran A. Market research on commercialization of innovative products of pharmasector: adsorptive carbon dressing in M. Gawron-Lapuszek, Y. Suchukova eds. Innovative Approaches To Ensuring the Quality of Education, Scientific Research and Technological Processes. Katowice. House University of Technology, 2021: 1171–9.

Tamai N, Mugita Y, Ikeda M, Sanada H. The relationship between malignant wound status and pain in breast cancer patients. Eur J Oncol Nurs 2016; 24: 8–12. https://doi.org/10.1016/j.ejon.2016.05.004

Downloads

Published

26.05.2023

How to Cite

Sakhno, L., Babenko, L., Lazarenko, L., Korotych, V., Sarnatskaya, V., Snezhkova, E., … Nikolaev, V. (2023). Efficacy of dispersed fibrous carbon sorbent in treatment of malignant fungating wounds. Experimental Oncology, 43(4), 359–364. https://doi.org/10.32471/exp-oncology.2312-8852.vol-43-no-4.16757

Issue

Vol. 43 No. 4 (2021): Experimental Oncology

Section

Original contributions

License

Copyright (c) 2023 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)